Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 701–800 of 1,003
Temperature-sensitive protein–DNA dimerizers
Hauschild, K. E., Metzler, R. E., Arndt, H., Moretti, R., Raffaelle, M., Dervan, P. B., & Ansari, A. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501289102 · Cited by 29
Chen, B., & Altman, R. B. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0614-4 · Cited by 28
“Most small molecule drugs inhibit their targets [8].”
BackgroundMizuhara, T., Moyano, D. F., & Rotello, V. M. (2016) · Nano Today · doi:10.1016/j.nantod.2015.11.002 · Cited by 30
Zhu, P., Yu, Z.-Z., Lv, Y.-F., Zhao, J., Tong, Y.-Y., You, Q., & Jiang, Z. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00682 · Cited by 29
Small‐molecule modulators of the OX 40– OX40 ligand co‐stimulatory protein–protein interaction
Song, Y. G., Margolles‐Clark, E., Bayer, A. L., & Buchwald, P. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12819 · Cited by 28
“Nevertheless, within the last few years, several sufficiently effective and even clinically promising small-molecule PPI inhibitors (PPIIs) have been identified for a number of different targets (Cochran, 2000; Arkin and Wells, 2004; Whitty and Kumaravel, 2006; Wells and McClendon, 2007; Buchwald, 2010).”
BackgroundInfluentialProtein interaction predictions from diverse sources
Liu, Y., Kim, I., & Zhao, H. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.01.005 · Cited by 30
“For these reasons, protein–protein interactions represent an important class of targets for human therapeutics and good annotation of protein interactions can greatly help drug discovery [1].”
BackgroundDiscovery of Selective Small-Molecule CD80 Inhibitors
Uvebrant, K., Thrige, D. D. G., Rosén, A., Åkesson, M., Berg, H., Walse, B., & Björk, P. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107300464 · Cited by 29
“Despite the disbelief in the likelihood of success in the small-molecule approach, there are recent examples that prove the validity of the concept: inhibition of lymphocyte function-associated antigen-1 (LFA-1) binding to intracellular adhesion molecule-1 and IL-2 inhibitors.(2) These examples show that only a small…”
BackgroundKnitting and untying the protein network: Modulation of protein ensembles as a therapeutic strategy
Gordo, S., & Giralt, E. (2009) · Protein Science · doi:10.1002/pro.43 · Cited by 30
Immekus, F., Barandun, L., Betz, M., Debaene, F., Petiot, S., Sanglier-Cianférani, S., Reuter, K., Diederich, F., & Klebe, G. (2013) · ACS Chemical Biology · doi:10.1021/cb400020b · Cited by 25
McFadden, M. J., Junop, M. S., & Brennan, J. D. (2010) · Analytical Chemistry · doi:10.1021/ac102164d · Cited by 28
Study of Functional and Allosteric Sites in Protein Superfamilies
Suplatov, D. A., & Švedas, V. K. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-4-34-45 · Cited by 28
A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model
Tsuburaya, N., Homma, K., Higuchi, T., Balia, A. G., Yamakoshi, H., Shibata, N., Nakamura, S., Nakagawa, H., Ikeda, S., Umezawa, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05127-2 · Cited by 30
Small Molecules as Anti-TNF Drugs
Richmond, V., Michelini, F. M., Bueno, C. A., Alché, L. E., & Ramirez, J. A. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150729115553 · Cited by 28
Synthesis of a Novel Macrocyclic Library: Discovery of an IGF-1R Inhibitor
Qvit, N., Reuveni, H., Gazal, S., Zundelevich, A., Blum, G., Niv, M. Y., Feldstein, A., Meushar, S., Shalev, D. E., Friedler, A., et al. (2008) · Journal of Combinatorial Chemistry · doi:10.1021/cc700113c · Cited by 28
Click Chemistry as a High‐Throughput Amenable Platform in Catalomics
Kalesh, K., Yang, P., Srinivasan, R., & Yao, S. Q. (2007) · QSAR & Combinatorial Science · doi:10.1002/qsar.200740064 · Cited by 28
Zhao, Y., Li, W., Zeng, J., Liu, G., & Tang, Y. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21955 · Cited by 29
Diversity-Oriented Synthesis of 13- to 18-Membered Macrolactams via Ring-Closing Metathesis
Dandapani, S., Lowe, J. T., Comer, E., & Marcaurelle, L. A. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2011957 · Cited by 27
Moon, H., Lee, W. S., Oh, M., Lee, H., Lee, J. H., Im, W., & Lim, H. (2014) · ACS Combinatorial Science · doi:10.1021/co500114f · Cited by 29
Ranganathan, A., Heine, P., Rudling, A., Plückthun, A., Kummer, L., & Carlsson, J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00646 · Cited by 29
Garifullina, A., & Shen, A. Q. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03780 · Cited by 28
Lead optimization in the nondrug-like space
Zhao, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.002 · Cited by 27
A Strategy Based on Protein–Protein Interface Motifs May Help in Identifying Drug Off-Targets
Engin, H. B., Keskin, Ö., Nussinov, R., & Gürsoy, A. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300072q · Cited by 28
Identification of a ubiquitin-binding interface using Rosetta and DEER
Tessmer, M. H., Anderson, D. M., Pickrum, A. M., Riegert, M. O., Moretti, R., Meiler, J., Feix, J. B., & Frank, D. W. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716861115 · Cited by 29
Melagraki, G., Ntougkos, E., Papadopoulou, D., Rinotas, V. E., Leonis, G., Douni, E. K., Afantitis, A., & Kollias, G. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00800 · Cited by 29
Hitting the Hot Spots of Cell Signaling Cascades
Grubb, G. J. J. (2006) · Science · doi:10.1126/science.1126903 · Cited by 27
Zhang, Z., Martiny, V. Y., Lagorce, D., Ikeguchi, Y., Alexov, E., & Miteva, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110884 · Cited by 26
“[17–24] or PPIs stabilizers [7,25–29].”
Tassa, C., Liong, M., Hilderbrand, S. A., Sandler, J. E., Reiner, T., Keliher, E. J., Weissleder, R., & Shaw, S. Y. (2012) · Lab on a Chip · doi:10.1039/c2lc40337d · Cited by 29
Muratcioğlu, S., Guven‐Maiorov, E., Keskin, Ö., & Gürsoy, A. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.10.001 · Cited by 26
Stephens, E. A., Ludwicki, M. B., Meksiriporn, B., Li, M., Ye, T., Monticello, C., Forsythe, K. J., Kummer, L., Zhou, P., Plückthun, A., et al. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00357 · Cited by 27
Ahanger, I. A., & Dar, T. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102538 · Cited by 27
Biron, É., & Bédard, F. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.006 · Cited by 28
Guntas, G., Lewis, S. M., Mulvaney, K. M., Cloer, E. W., Tripathy, A., Lane, T. R., Major, M. B., & Kuhlman, B. A. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv055 · Cited by 26
Butini, S., Guarino, E., Campiani, G., Brindisi, M., Coccone, S. S., Fiorini, I., Novellino, E., Belinskaya, T., Saxena, A., & Gemma, S. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.076 · Cited by 26
Wu, Y., Olsen, L. B., Lau, Y. H., Jensen, C. H., Rossmann, M., Baker, Y. R., Sore, H. F., Collins, S., & Spring, D. R. (2016) · ChemBioChem · doi:10.1002/cbic.201500648 · Cited by 32
Chiral Sulfoxide-Induced Single Turn Peptide α-Helicity
Zhang, Q., Jiang, F., Zhao, B., Lin, H., Tian, Y., Xie, M., Bai, G., Gilbert, A. M., Goetz, G. H., Liras, S. I., et al. (2016) · Scientific Reports · doi:10.1038/srep38573 · Cited by 26
The Subtle Trade-Off between Evolutionary and Energetic Constraints in Protein–Protein Interactions
Marchetti, F., Capelli, R., Rizzato, F., Laio, A., & Colombo, G. (2019) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.9b00191 · Cited by 26
Autoinhibited proteins as promising drug targets
Peterson, J. R., & Golemis, E. A. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20184 · Cited by 26
Natural product-inspired strategies towards the discovery of novel bioactive molecules
Gagare, S. S., Patil, P., & Jain, A. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00627-z · Cited by 32
“Thus, modulating protein–protein interaction is one of the attractive drug discovery concepts [21].”
BackgroundFloris, M., & Moro, S. (2011) · Molecular Informatics · doi:10.1002/minf.201100093 · Cited by 25
Prediction of binding hot spot residues by using structural and evolutionary parameters
Higa, R. H., & Tozzi, C. L. (2009) · Genetics and Molecular Biology · doi:10.1590/s1415-47572009000300029 · Cited by 28
“Recent interest in this protein-protein interface as drug targets (Arkin and Wells, 2004) has highlighted the importance of identifying hot spots systematically.”
BackgroundRubin, S. J. S., Tal‐Gan, Y., Gilon, C., & Qvit, N. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180518094322 · Cited by 25
“The importance of PPIs is demonstrated by their frequent dysregulation in disease [1] and is also reflected by the large number of studies dedicated to this subject, some of which are described in the following reviews [2–4].”
BackgroundTargeting Epigenetic protein–protein Interactions With small-molecule Inhibitors
Linhares, B. M., Grembecka, J. E., & Cierpicki, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0082 · Cited by 26
Oncogenic and tumor suppressor function of MEIS and associated factors
Girgin, B., Alpaslan, M. K., & Kocabaş, F. (2020) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2006-25 · Cited by 26
“Targeting MEIS, its associated partners and pathways in cancer Small molecules alter the activity or function of target macromolecules by binding to them (Arkin and Wells, 2004).”
BackgroundRibosomal synthesis of nonstandard peptides.
Kang, T., & Suga, H. (2008) · Biochemistry and cell biology = Biochimie et biologie cellulaire · doi:10.1139/o08-009 · Cited by 26
“Additionally, small, deep cavities that can serve as binding sites for small organic molecules are rarely found at the interface of protein–protein interaction pairs (Arkin and Wells 2004).”
BackgroundZhang, W., Penmatsa, H., Ren, A., Punchihewa, C., Lemoff, A. S., Yan, B., Fujii, N., & Naren, A. P. (2011) · Biochemical Journal · doi:10.1042/bj20101725 · Cited by 30
Veselovsky, A. V., Zharkova, M. S., Poroikov, V., & Nicklaus, M. C. (2014) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2014.898689 · Cited by 25
“Hot spots are generally located near the centre of protein – protein interfaces, away from solvent, but rarely form continuous regions [11,12].”
BackgroundProtein Surface Recognition: Structural Characterisation of Cytochrome c–Porphyrin Complexes
Crowley, P. B., Ganji, P., & Ibrahim, H. (2008) · ChemBioChem · doi:10.1002/cbic.200700736 · Cited by 25
Direct monitoring of protein–protein inhibition using nano electrospray ionization mass spectrometry
Cubrilovic, D., Barylyuk, K., Hofmann, D., Walczak, M., Gräber, M., Berg, T., Wider, G., & Zenobi, R. (2014) · Chemical Science · doi:10.1039/c3sc53360c · Cited by 27
Inhibition of Ral GTPases Using a Stapled Peptide Approach
Thomas, J. C., Cooper, J. M., Clayton, N. S., Wang, C., White, M. A., Abell, C., Owen, D., & Mott, H. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720243 · Cited by 26
Benard, S., Smith, T. M., Cunningham, K. M., Jacob, J., Desilva, T., Lin, L., Shaw, G. D., Kriz, R., & Kelleher, K. S. (2008) · Biochemistry · doi:10.1021/bi702428q · Cited by 25
Wang, H., HAN, H., Mousses, S., & VonHoff, D. D. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.013 · Cited by 33
From Protein—Protein Complexes to Interactomics
Collura, V., & Boissy, G. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5943-8_8 · Cited by 30
Evolution of Class-Specific Peptides Targeting a Hot Spot of the Gαs Subunit
Austin, R. J., Ja, W. W., & Roberts, R. W. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.01.032 · Cited by 25
Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions
Sugaya, N., & Furuya, T. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-50 · Cited by 28
“These PPIs were selected from review articles focusing on druggable PPIs [1-4 , (cid:129) A PPI-inhibiting small chemical has been identified, and its potency as a PPI inhibitor has been validated by in vitro and/or in vivo assays.”
BackgroundUse of Click-Chemistry in the Development of Peptidomimetic Enzyme Inhibitors
Fabbrizzi, P., Menchi, G., Guarna, A., & Trabocchi, A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131218093611 · Cited by 24
Macrocyclic Glycohybrid Toolbox Identifies Novel Antiangiogenesis Agents from Zebrafish Assay
Dasari, B., Jogula, S., Borhade, R., Sridhar, B., Chandrasekar, G., Kitambi, S. S., & Arya, P. (2013) · Organic Letters · doi:10.1021/ol3032297 · Cited by 24
Long, M. J. C., Rogg, C., & Aye, Y. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00537 · Cited by 26
Bazzoli, A., Kelow, S. P., & Karanicolas, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140359 · Cited by 27
Lindh, M., Svensson, F., Schaal, W., Zhang, J., Sköld, C., Brandt, P., & Karlén, A. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci5005465 · Cited by 25
Enthammer, M., Papadakis, E. S., Gachet, M. S., Deutsch, M., Schwaiger, S., Kozieł, K., Ashraf, M., Khalid, S., Wolber, G., Packham, G. K., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0142 · Cited by 30
“bioguided isolation protocol to identify the compounds responsible for the biologic activity of Thioflavin S (37).”
BackgroundDevelopment of Protein–Protein Interaction Inhibitors for the Treatment of Infectious Diseases
Voter, A. F., & Keck, J. L. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.07.005 · Cited by 24
“…M anuscript A uthor M anuscript A uthor M anuscript In the face of a dry anti-infective pipeline, researchers and pharmaceutic companies have begun to turn their attention to a different class of targets, protein-protein interactions (PPI) (Michelle R. Arkin & Wells, 2004; Wells & McClendon, 2007).”
NTRK1 is a positive regulator of YAP oncogenic function
Yang, X., Shen, H., Buckley, B., Chen, Y., Yang, N., Mussell, A. L., Chernov, M., Kobzik, L., Frangou, C. G., Han, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0609-1 · Cited by 25
Sequence‐Based Design of α/β‐Peptide Foldamers That Mimic BH3 Domains
Horne, W. S., Boersma, M., Windsor, M. A., & Gellman, S. H. (2008) · Angewandte Chemie · doi:10.1002/ange.200705315 · Cited by 25
Techniques for Molecular Imaging Probe Design
Reynolds, F., & Kelly, K. A. (2011) · Molecular Imaging · doi:10.2310/7290.2011.00003 · Cited by 25
“Most proteins bind to other proteins through relatively small areas(64) (hot spots), which tend to be areas that phage peptide sequences also bind to.(64,65) Constrained libraries have peptides that are forced into a limited number of configurations, an example of which is the disulfideconstrained libraries.”
BackgroundOptimization of CD4/gp120 Inhibitors by Thermodynamic‐Guided Alanine‐Scanning Mutagenesis
Liu, Y., Schön, A., & Freire, E. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12075 · Cited by 24
Prakesch, M. A., Srivastava, S., Leek, D. M., & Arya, P. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc060059n · Cited by 24
Sugaya, N., Ikeda, K., Tashiro, T., Takeda, S., Otomo, J., Ishida, Y., Shiratori, A., Toyoda, A., Noguchi, H., Takeda, T., et al. (2007) · BMC Pharmacology · doi:10.1186/1471-2210-7-10 · Cited by 28
“These PPIs utilizing α -helix grooves are thought to be amenable to small-molecule drug discovery [1], and thus may be promising targets of PPI-inhibiting SDCs [1,5].”
BackgroundMethodInfluentialWhen analoging is not enough: scaffold discovery in medicinal chemistry
Zhao, H., & Akritopoulou‐Zanze, I. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903584874 · Cited by 25
“1 Targeting protein–protein interactions Protein–protein interactions are central to many key cellular signaling pathways and are, therefore, potential drug targets [22].”
BackgroundRyu, M., Oh, S., Jeong, K., Hwang, S., Kim, J., Chung, M., & Chi, S. (2024) · ACS Nano · doi:10.1021/acsnano.4c11436 · Cited by 23
Afonso, A. L., Cavaleiro, C. T., Castanho, M. A. R. B., Neves, V., & Cavaco, M. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073117 · Cited by 30
Thangarasu, P., Alagumuthu, M., & Thamaraiselvi, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.02.003 · Cited by 23
Shoji, A., Kang, C., Fujioka, K., Rose, J. P., & Sun, R. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00661 · Cited by 24
Jogula, S., Dasari, B., Khatravath, M., Chandrasekar, G., Kitambi, S. S., & Arya, P. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201300548 · Cited by 23
Targeting Protein-Protein Interactions for Parasite Control
Taylor, C. M., Fischer, K., Abubucker, S., Wang, Z., Martin, J. C., Jiang, D., Magliano, M., Rosso, M., Li, B.-W., Fischer, P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018381 · Cited by 24
“PPIs are of central importance and are involved in nearly all cellular processes[22], making these interactions important targets for drug discovery[23].”
BackgroundHu, G., Li, X., Sun, X., Lü, W., Liu, G., Huang, J. Y., Shen, X., & Tang, Y. (2012) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1494-0 · Cited by 25
Krall, N., Scheuermann, J., & Neri, D. (2013) · Angewandte Chemie · doi:10.1002/ange.201204631 · Cited by 23
Thermal Shift as an Entropy-Driven Effect
Redhead, M. A., Satchell, R., McCarthy, C., Pollack, S. J., & Unitt, J. F. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00860 · Cited by 23
Sameshima, T., Yamamoto, T., Sano, O., Sogabe, S., Igaki, S., Sakamoto, K., Ida, K., Gotou, M., Imaeda, Y., Sakamoto, J., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00732 · Cited by 27
Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach
Paciotti, R., Agamennone, M., Coletti, C., & Storchi, L. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00306-0 · Cited by 23
Chaurasia, P., Mezei, M., Zhou, M., & Ossowski, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004617 · Cited by 23
“spots’’) [31] for review, might be responsible for the high affinity protein/protein interaction.”
BackgroundWeidemann, T., Höfinger, S., Müller, K., & Auer, M. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.095 · Cited by 23
Break CDK2/Cyclin E1 Interface Allosterically with Small Peptides
Chen, H., Zhao, Y., Li, H., Zhang, D., Huang, Y., Shen, Q., Duyne, R. V., Kashanchi, F., Zeng, C., & Liu, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109154 · Cited by 26
An in silico approach for the discovery of CDK5/p25 interaction inhibitors
Zhang, B., Corbel, C., Guéritte, F., Couturier, C., Bach, S., & Tan, V. B. C. (2011) · Biotechnology Journal · doi:10.1002/biot.201100139 · Cited by 27
“KGaA, Weinheim 873 the general lack of small molecule starting points for drug design, the PPI interfaces have proven to be particularly elusive drug targets and have been deemed intractable in many instances [23–25].”
BackgroundComputational Techniques in Fragment Based Drug Discovery
Villar, H. O., & Hansen, M. H. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782194725 · Cited by 24
Joshi, P. B., Hirst, M., Malcolm, T., Parent, J., Mitchell, D., Lund, K., & Sadowski, I. (2007) · BioTechniques · doi:10.2144/000112434 · Cited by 24
Incomplete Protein Packing as a Selectivity Filter in Drug Design
Fernández, A. (2005) · Structure · doi:10.1016/j.str.2005.08.018 · Cited by 25
“In such cases, ligand affinity is attributed to the intermolecular hydrogen-bonding propensities of the inhibitor, inferred from protein-substrate transition-state mimetics (Wlodawer and Vondrasek, 1998;Arkin and Wells, 2004;Katz et al., 2000;Steinmetzer et al., 2001).”
BackgroundNew therapeutic targets in immune disorders: ItpkB, Orai1 and UNC93B
Huang, Y. H., Hoebe, K. H. N., & Sauer, K. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.4.391 · Cited by 24
“Although traditionally considered difficult, successful inhibition of protein – protein interactions with small molecules has now been achieved for a number of targets [119-121] .”
BackgroundThiel, P., Kaiser, M., & Ottmann, C. (2012) · Angewandte Chemie · doi:10.1002/ange.201107616 · Cited by 25
A New Methodology for Incorporating Chiral Linkers into Stapled Peptides
Serrano, J. C., Sipthorp, J., Xu, W., Itzhaki, L. S., & Ley, S. V. (2017) · ChemBioChem · doi:10.1002/cbic.201700075 · Cited by 24
MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation
Li, S., Chen, J., Li, X., bai, X., & Shi, D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115781 · Cited by 24
Detection of molecular binding via charge-induced mechanical response of optical fibers
Guan, Y., Shan, X., Wang, S., Zhang, P., & Tao, N. J. (2014) · Chemical Science · doi:10.1039/c4sc01188k · Cited by 22
Exploiting the P-1 Pocket of BRCT Domains Toward a Structure Guided Inhibitor Design
Yuan, Z., Kumar, E. A., Campbell, S. J., Palermo, N. Y., Kizhake, S., Glover, J. N. M., & Natarajan, A. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200147a · Cited by 28
Peterson‐Kaufman, K. J., Sadowsky, J., Scheef, E. A., Pal, S., Kourentzi, K. D., Willson, R. C., Bresnick, E. H., Sheibani, N., & Gellman, S. H. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.03.043 · Cited by 22
“[27] It is very challenging to identify small molecules that bind tightly and specifically to a given protein surface due to the relatively flat surface of the interaction;[28, 29] typically, thousands of inhibitor candidates must be screened.”
BackgroundPeptide Inhibitors of Viral Assembly: A Novel Route to Broad-Spectrum Antivirals
ElSawy, K. M., Twarock, R., Verma, C. S., & Caves, L. S. D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200467s · Cited by 25
Synthesis of Chondramide A Analogues with Modified β‐Tyrosine and Their Biological Evaluation
Zhdanko, A. G., Schmauder, A., Christopher, I. L., Sibley, L. D., Sept, D., Sasse, F., & Maier, M. E. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201101978 · Cited by 22
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2006) · International Journal of Quantum Chemistry · doi:10.1002/qua.21193 · Cited by 26
Gowthaman, R., Miller, S. A., Rogers, S. A., Khowsathit, J., Lan, L., Bai, N., Johnson, D. K., Liu, C., Xu, L., Anbanandam, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00150 · Cited by 25
Wang, Z. A., Ding, X., Tian, C., & Zheng, J. (2016) · RSC Advances · doi:10.1039/c6ra13976k · Cited by 23
Shi, D., Zhou, S., Liu, X., Zhao, C., Liu, H., & Yao, X. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.11.022 · Cited by 22
High-throughput identification of dominant negative polypeptides in yeast
Dorrity, M. W., Queitsch, C., & Fields, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0368-0 · Cited by 25
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.